BR9914527A - Vetores de replicação seletiva viral - Google Patents

Vetores de replicação seletiva viral

Info

Publication number
BR9914527A
BR9914527A BR9914527-8A BR9914527A BR9914527A BR 9914527 A BR9914527 A BR 9914527A BR 9914527 A BR9914527 A BR 9914527A BR 9914527 A BR9914527 A BR 9914527A
Authority
BR
Brazil
Prior art keywords
vectors
virus
cell
target cell
replication
Prior art date
Application number
BR9914527-8A
Other languages
English (en)
Inventor
Muralidhara Ramachandra
Paul W Shabram
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of BR9914527A publication Critical patent/BR9914527A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"VETORES DE REPLICAçãO SELETIVA VIRAL'' <D>A presente invenção fornece vírus recombinantes que replicam seletivamente o genoma viral em resposta às condições intracelulares da célula alvo, através do uso de um promotor responsivo de percurso, que substancialmente inibe a replicação viral na célula hospedeira, com base no fenótipo ou genótipo da célula infectada. Na célula alvo, o elemento que promove o promotor responsivo de percurso é <MU>inativo<MV> e, portanto, o vírus é permitido replicar. Isso resulta em: (1) morte das células pela natureza lítica natural do vírus e/ou (2) proporciona uma dose terapêutica de um produto de transgene (amplificado em comparação aos vetores imcompetentes de replicação) para a célula alvo e (3) produz uma concentração localizada do vírus que facilita a infecção das células adjacentes ao vírus recombinante. A invenção ainda fornece métodos terapêuticos e de diagnóstico do uso dos vetores, formulações farmacêuticas compreendendo os vetores, métodos de fabricação dos vetores e células transformadas compreendendo os vetores.
BR9914527-8A 1998-10-15 1999-10-14 Vetores de replicação seletiva viral BR9914527A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17268698A 1998-10-15 1998-10-15
PCT/US1999/021452 WO2000022137A2 (en) 1998-10-15 1999-10-14 Selectively replicating viral vectors

Publications (1)

Publication Number Publication Date
BR9914527A true BR9914527A (pt) 2001-06-26

Family

ID=22628758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914527-8A BR9914527A (pt) 1998-10-15 1999-10-14 Vetores de replicação seletiva viral

Country Status (21)

Country Link
EP (1) EP1121441B1 (pt)
JP (2) JP4404490B2 (pt)
KR (1) KR100841815B1 (pt)
CN (2) CN101092636B (pt)
AR (1) AR020897A1 (pt)
AT (1) ATE348169T1 (pt)
AU (1) AU758354B2 (pt)
BR (1) BR9914527A (pt)
CA (1) CA2345900A1 (pt)
CZ (1) CZ301506B6 (pt)
DE (1) DE69934421T2 (pt)
ES (1) ES2279636T3 (pt)
HK (1) HK1040529B (pt)
HU (1) HU226602B1 (pt)
IL (2) IL142337A0 (pt)
NO (1) NO330666B1 (pt)
NZ (2) NZ528283A (pt)
PL (1) PL347898A1 (pt)
SK (1) SK4412001A3 (pt)
TW (1) TWI262948B (pt)
WO (1) WO2000022137A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU758354B2 (en) * 1998-10-15 2003-03-20 Canji, Inc. Selectively replicating viral vectors
KR100492017B1 (ko) * 2002-06-24 2005-05-30 학교법인고려중앙학원 인간 간엽줄기 세포를 이용한 항암치료방법
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2013138650A1 (en) * 2012-03-14 2013-09-19 Salk Institute For Biological Studies Adenoviral tumor diagnostics
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2019020992A1 (en) * 2017-07-25 2019-01-31 Oxford Genetics Limited ADENOVIRAL VECTOR
US11485957B2 (en) * 2017-10-10 2022-11-01 Nantbio, Inc. Modified EC7 cells having low toxicity to viral production payloads

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE178490T1 (de) * 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
WO1998013508A1 (en) * 1996-09-24 1998-04-02 Dana-Farber Cancer Institute Method of targeting malignant cells using an e2f responsive promoter
IL129922A0 (en) * 1996-11-15 2000-02-29 Canji Inc Tissue specific expression of retinoblastoma protein
AU744725B2 (en) * 1997-03-03 2002-02-28 Cold Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
AU758354B2 (en) * 1998-10-15 2003-03-20 Canji, Inc. Selectively replicating viral vectors

Also Published As

Publication number Publication date
HUP0104107A3 (en) 2003-09-29
NO20011843D0 (no) 2001-04-10
DE69934421T2 (de) 2007-10-11
NO330666B1 (no) 2011-06-06
IL142337A (en) 2009-05-04
JP2009254385A (ja) 2009-11-05
IL142337A0 (en) 2002-03-10
HK1040529B (zh) 2007-02-09
KR20020013472A (ko) 2002-02-20
AR020897A1 (es) 2002-06-05
CN1330715A (zh) 2002-01-09
JP2002541761A (ja) 2002-12-10
EP1121441A2 (en) 2001-08-08
AU6391599A (en) 2000-05-01
PL347898A1 (en) 2002-04-22
WO2000022137A3 (en) 2000-08-03
HK1040529A1 (en) 2002-06-14
EP1121441B1 (en) 2006-12-13
HU226602B1 (en) 2009-04-28
TWI262948B (en) 2006-10-01
KR100841815B1 (ko) 2008-06-26
CZ301506B6 (cs) 2010-03-31
ES2279636T3 (es) 2007-08-16
CZ20011129A3 (cs) 2002-01-16
CA2345900A1 (en) 2000-04-20
NO20011843L (no) 2001-06-14
ATE348169T1 (de) 2007-01-15
SK4412001A3 (en) 2001-12-03
JP4404490B2 (ja) 2010-01-27
DE69934421D1 (de) 2007-01-25
CN101092636B (zh) 2012-08-08
CN101092636A (zh) 2007-12-26
CN1325647C (zh) 2007-07-11
NZ510805A (en) 2003-12-19
HUP0104107A2 (hu) 2002-03-28
AU758354B2 (en) 2003-03-20
WO2000022137A2 (en) 2000-04-20
NZ528283A (en) 2005-05-27

Similar Documents

Publication Publication Date Title
JP6817979B2 (ja) 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
Evans et al. Development of stable liquid formulations for adenovirus-based vaccines
BR9914527A (pt) Vetores de replicação seletiva viral
Powell et al. An IkappaB homolog encoded by African swine fever virus provides a novel mechanism for downregulation of proinflammatory cytokine responses in host macrophages
Gomez-Foix et al. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism.
Lin et al. Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene
US6630344B1 (en) Diminishing viral gene expression by promoter replacement
Marcellus et al. Induction of p53-independent apoptosis by the adenovirus E4orf4 protein requires binding to the Bα subunit of protein phosphatase 2A
ES2288488T3 (es) Adenovirus oncoliticos.
Lucas et al. Infection of mouse neurones by West Nile virus is modulated by the interferon‐inducible 2′‐5′ oligoadenylate synthetase 1b protein
Aldabe et al. Poliovirus protein 2BC increases cytosolic free calcium concentrations
Humlová et al. Vaccinia virus induces apoptosis of infected macrophages
PT931830E (pt) Virus citopaticos para terapia e profilaxia de neoplasia
Wold Adenovirus genes that modulate the sensitivity of virus‐infected cells to lysis by TNF
Liu et al. Dioscin's antiviral effect in vitro
Di Pasquale et al. PKA/PrKX activity is a modulator of AAV/adenovirus interaction
Wolff et al. Cleavage of the Junin virus nucleoprotein serves a decoy function to inhibit the induction of apoptosis during infection
Itoh et al. Increased induction of apoptosis by a Sendai virus mutant is associated with attenuation of mouse pathogenicity
Becker et al. Isolation and characterization of cidofovir resistant vaccinia viruses
Hurtado et al. Antiviral activity of lauryl gallate against animal viruses
Chepurnov et al. Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125-kDa GP viral protein
Zou et al. Overexpression of adenovirus E3-11.6 K protein induces cell killing by both caspase-dependent and caspase-independent mechanisms
Ahmed et al. Peptide mimetics of gamma interferon possess antiviral properties against vaccinia virus and other viruses in the presence of poxvirus B8R protein
Pang et al. In vitro inhibition of Japanese encephalitis virus replication by capsid-targeted virus inactivation
Pichlmair et al. Thogoto virus lacking interferon-antagonistic protein ML is strongly attenuated in newborn Mx1-positive but not Mx1-negative mice

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.